Eupraxia Pharmaceuticals (EPRX) Net Income Attributable to Noncontrolling Interests (2023 - 2026)
Eupraxia Pharmaceuticals (EPRX) recorded Net Income Attributable to Noncontrolling Interests of -$6,478 in Q2 2026, compared with -$6,767 a year earlier.
Powered by 
Analysis
Eupraxia Pharmaceuticals (EPRX) Net Income Attributable to Noncontrolling Interests (2023 - 2026) Analysis & Trends
On a TTM basis, Eupraxia Pharmaceuticals' Net Income Attributable to Noncontrolling Interests came in at -$25,968 as of Jun 30, 2026; for FY2025, it came in at -$29,509.
- Across earlier years, Net Income Attributable to Noncontrolling Interests came in at -$241,953 in FY2024, -$745,210 in FY2023 and -$501,135 in FY2022.
- Quarterly Net Income Attributable to Noncontrolling Interests has ranged from -$380,394 in Q4 2023 to -$1,415 in Q1 2026 over the past five years.
- Per Business Quant, the preceding three quarters came in at -$1,415 (Q1 2026), -$10,084 (Q4 2025) and -$7,991 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Eupraxia Pharmaceuticals | 304.87 Mn | -174.66 Mn | - | -6,189.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -6,189.00 |
| Jun 30, 2026 | -6,478.00 |
| Mar 31, 2026 | -1,415.00 |
| Dec 31, 2025 | -10,084.00 |
| Sep 30, 2025 | -7,991.00 |
| Jun 30, 2025 | -6,767.00 |
| Mar 31, 2025 | -4,667.00 |
| Dec 31, 2024 | -23,385.00 |
| Sep 30, 2024 | -47,995.00 |
| Jun 30, 2024 | -56,678.00 |
| Mar 31, 2024 | -113,895.00 |
| Dec 31, 2023 | -380,394.00 |
| Sep 30, 2023 | -174,741.00 |
| Jun 30, 2023 | -129,379.00 |
| Mar 31, 2023 | -60,696.00 |
API Access
Eupraxia Pharmaceuticals Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=EPRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "EPRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=EPRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();